PT  - JOURNAL ARTICLE
AU  - Herzberg, Jonas
AU  - Vollmer, Tanja
AU  - Fischer, Bastian
AU  - Becher, Heiko
AU  - Becker, Ann-Kristin
AU  - Honarpisheh, Human
AU  - Guraya, Salman Yousuf
AU  - Strate, Tim
AU  - Knabbe, Cornelius
TI  - SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study
AID  - 10.1101/2021.06.09.21258648
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.09.21258648
4099  - http://medrxiv.org/content/early/2021/06/13/2021.06.09.21258648.short
4100  - http://medrxiv.org/content/early/2021/06/13/2021.06.09.21258648.full
AB  - Background Following a year of development, several vaccines have been approved to contain the global COVID-19 pandemic. Real world comparative data on immune response following vaccination or natural infection are rare.Methods We conducted a longitudinal observational study in employees at a secondary care hospital affected by the COVID-19 pandemic. Comparisons were made about the presence of anti-SARS-CoV-2 immunglobulin G (IgG) antibody ratio after natural infection, or vaccination with one or two doses of BioNTech/Pfizer (BNT162b2), or one dose of AstraZenca (Vaxzevria) vaccine.Results We found a 100% humoral response rate in participants after 2 doses of BNT162b2 vaccine. The antibody ratio in participants with one dose BNT162b2 and Vaxzevria did not differ significantly to those with previous PCR-confirmed infection, whereas this was significantly lower in comparison to two doses of BioNTech/Pfizer. We could not identify a correlation with previous comorbidities, obesity or age within this study. Smoking showed a negative effect on the antibody response (p=0.006)Conclusion Our data provide an overview about humoral immune response after natural SARS-CoV-2 infection or following vaccination, and supports the usage of booster vaccinations, especially in patients after a natural SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00021270Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Medical Association Schleswig-Holstein approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data generated and analysed during this study are available from the corresponding author on reasonable request.